Clopidogrel Tablet, Film Coated
Product Images NDC 68071-3319

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 68071-3319). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 3319 9 (2)

This text provides detailed information about Clopidogrel 75mg tablets from NuCare Pharmaceuticals. It includes the National Drug Code (NDC), product description, ingredients, dosage, and storage instructions. It also reminds users to consult a doctor or pharmacist for advice regarding side effects and emphasizes keeping the product out of reach of children and storing it at a controlled temperature of 68.77°F.*

FDA Label Image

Figure 1 (Clopidogrel Fig1)

This text provides information about the exposure to the Clopidogrel Active Metabolite following multiple doses of Clopidogrel Bisulfate 75 mg alone or with Proton Pump Inhibitors (PPIs). It also outlines the co-administered PPIs' effect on the active metabolite area under the curve (AUC), showing mean and 90% confidence intervals for different PPIs including Dexlansoprazole, Lansoprazole, Pantoprazole, and Omeprazole. The text hints at comparing the change relative to Clopidogrel Bisulfate administered alone.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Fig2)

This text provides information about the cumulative event rate (%) for cardiovascular death, myocardial infarction, and stroke over months of follow-up for two treatment groups. The results show that Clopidogrel Bisulfate (+ aspirin) had a significantly lower event rate compared to Plagebo (+ aspirin), with a p-value of 0.00009. Other standard therapies were also used during the study.*

FDA Label Image

Figure 3: Hazard Ratio For Patient Baseline Characteristics And On-study Concomitant Medications/interventions For The Cure Study (Clopidogrel Fig3)

This document appears to contain a chart or table related to medical information, likely pertaining to medications and their effects on different conditions such as diabetes, myocardial infarction, and stroke. The table seems to compare various treatments and their outcomes, potentially including medications like Heparin, Aspirin, Clopidogrel, and Bisultate. The document also mentions Hazard Ratio but the complete context is not fully visible.*

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Fig4)

This text provides data on mortality rates in a clinical trial comparing Placebo and Clopidogrel. Placebo had 1845 deaths (8.1%), while Clopidogrel had 1726 deaths (7.5%). A 7% proportional risk reduction was observed with Clopidogrel (p = 0.03) over the 28-day follow-up period.*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study (Clopidogrel Fig5)

This text appears to be displaying data related to the percentage of events for patients taking Placebo and Clopidogrel over different time intervals since randomization, up to 28 days. It includes information about proportional risk reduction in death, re-infarction, or stroke. The data seems to be comparing the incidence of events in patients receiving Placebo versus Clopidogrel after a certain period of time since randomization.*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel Fig6)

FDA Label Image

Figure 7: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Fig7)

This is a chart showing the cumulative event rates for fatal or non-fatal vascular events over a follow-up period of 36 months. The data compares the effects of aspirin and clopidogrel bisulfate over time.*

FDA Label Image

Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Clopidogrel Fig8)

This is a table showing the results of a study evaluating the use of Clopidogrel Bisulfate versus Aspirin in patients with Stroke, Mi (Myocardial infarction), and PAD (Peripheral artery disease). The table provides the number and percentage of patients in each category, along with the Hazard Ratio and Confidence Interval. It indicates that Clopidogrel Bisulfate may have favorable outcomes over Aspirin in certain conditions as seen in the table "Favors Clopidogrel Bisulfate" and "Favors Aspirin".*

FDA Label Image

Chemical Structure (Clopidogrel Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.